Try our beta test site

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by European Organisation for Research and Treatment of Cancer - EORTC
Sponsor:
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT01402271
First received: July 23, 2011
Last updated: October 11, 2016
Last verified: October 2016
  Purpose

RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of pazopanib hydrochloride when given together with paclitaxel and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.


Condition Intervention Phase
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Drug: carboplatin
Drug: paclitaxel
Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma

Resource links provided by NLM:


Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Maximum-tolerated dose of pazopanib hydrochloride, carboplatin, and paclitaxel (phase I)
  • Progression-free survival according to RECIST 1.1 at 1 year (phase II)

Secondary Outcome Measures:
  • Pharmacokinetics of pazopanib, carboplatin, and paclitaxel (phase I)
  • Safety and tolerability according to CTCAE 4.0 (phase I and phase II)
  • Response rate (phase I and phase II)
  • Predictive biomarkers (phase I and phase II)
  • Overall survival (phase II)
  • Age-related subanalysis for toxicity and efficacy (cut-off 65 years old) (phase II)

Estimated Enrollment: 88
Study Start Date: July 2012
Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: pazopanib in combination with paclitaxel and carboplatin
Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
Drug: carboplatin Drug: paclitaxel Drug: pazopanib hydrochloride Other: laboratory biomarker analysis Other: pharmacological study
Active Comparator: Paclitaxel and carboplatin only
Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
Drug: carboplatin Drug: paclitaxel Drug: pazopanib hydrochloride

Detailed Description:

OBJECTIVES:

Primary

  • To determine the maximum-tolerated dose of pazopanib hydrochloride in combination with paclitaxel and carboplatin in patients with platinum-refractory or -resistant ovarian epithelial, fallopian tube, or peritoneal carcinoma. (Phase I)
  • To determine the progression-free survival (PFS) at 1 year according to the RECIST 1.1 in these patients. (Phase II)

Secondary

  • To determine the safety and adverse event profiles in these patients. (Phase I and phase II)
  • To determine the pharmacokinetics (PK) of this regimen using intensive sampling. (Phase I)
  • To determine if there is PK interaction (and if so, what kind of PK interaction) between carboplatin and paclitaxel as well as pazopanib hydrochloride. (Phase I)
  • To determine the response rate (RR) in these patients. (Phase I)
  • To determine and evaluate predictive biomarkers. (Phase I and phase II)
  • To determine the RR, overall survival (OS), and PFS of these patients. (Phase II)

OUTLINE: This is a multicenter, phase I, dose-escalation study of carboplatin, paclitaxel, and pazopanib hydrochloride followed by a phase II randomized study.

  • Phase I: Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 30 minutes on day 1. Patients also receive oral pazopanib hydrochloride* once daily on days 2-7. Treatment repeats every week for up to 18 courses**. Patients then continue to receive oral pazopanib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.

NOTE: *Pazopanib hydrochloride is started in course 2 in order to evaluate the pharmacokinetic of paclitaxel and carboplatin prior to pazopanib hydrochloride administration.

  • Phase II: Patients are stratified according to center, disease status (platinum-refractory vs -resistant) and number of prior lines of treatment (1 vs more than 1). Patients are randomized in a 2:1 ratio (arm II [experimental arm]: arm I [standard arm]) to 1 of 2 treatment arms.

    • Arm I (standard arm): Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every week for up to 18 courses.
    • Arm II (experimental arm): Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive oral pazopanib hydrochloride once daily on days 2-7. Treatment repeats every week for up to 18 courses**. Patients then continue to receive oral pazopanib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.

NOTE: **After course 9, chemotherapy will be interrupted for 1 week.

Blood samples are collected from some patients periodically for pharmacokinetic and biomarker studies.

After completion of study treatment, patients are followed up at 3 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal carcinoma

    • Recurrent disease
  • Received at least 1 prior platinum treatment and developed platinum-refractory disease (i.e., progression within 4 weeks of platinum administration) or platinum-resistant disease (i.e., progression within 6 months after the last platinum dose)

    • There is no restriction on the number of prior lines of treatment
    • Non-platinum treatment is allowed after proven platinum-resistance or -refractory disease
  • Evaluable (measurable or nonmeasurable) disease according to RECIST version 1.1 criteria
  • Patients with refractory disease on weekly paclitaxel and carboplatin regimen are excluded (phase II only)
  • No known gastrointestinal intraluminal metastatic lesions with risk of bleeding
  • No known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
  • No known brain metastases or leptomeningeal disease

PATIENT CHARACTERISTICS:

  • WHO performance status 0-2
  • Absolute neutrophil count ≥ 1.5 x 10^9/L
  • Hemoglobin ≥ 9 g/dL
  • Platelet count ≥ 100 x 10^9/L
  • PT, aPTT, or INR ≤ 1.2 times upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 times ULN*
  • ALT and AST ≤ 2.5 times ULN*
  • Serum creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 50 mL/min
  • Urine protein creatinine ratio < 1 OR 24-hour urine protein < 1 g
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during study therapy
  • No other prior primary or recurrent malignancies treated within the past 2 years except for completely resected non-melanomatous skin carcinoma or successfully treated carcinoma in situ of the skin or uterine cervix
  • No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs similar or related to paclitaxel, carboplatin, and pazopanib hydrochloride
  • Able to receive infusions of paclitaxel and carboplatin
  • Able to swallow pazopanib hydrochloride tablets
  • No unstable or serious condition (e.g., uncontrolled infection requiring systemic therapy)
  • No history of any of the following cardiovascular conditions within the past 6 months:

    • Myocardial infarction
    • Unstable angina
    • Symptomatic peripheral vascular disease
    • NYHA class III-IV congestive heart failure
  • LVEF > 50% as assessed by ultrasound or MUGA scan, if clinically indicated
  • No inadequately controlled hypertension (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg)

    • Initiation or adjustment of blood pressure medication is permitted prior to the study entry
  • No prolonged corrected QT interval (QTc) defined as > 480 msecs using Bazett formula
  • No history of cerebrovascular accident within the past 6 months, including any of the following:

    • Transient ischemic attack
    • Pulmonary embolism
    • Untreated deep venous thrombosis (DVT)

      • Patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
  • No evidence of active bleeding or bleeding diathesis
  • No clinically significant gastrointestinal (GI) tract abnormalities that may increase the risk for GI bleeding including, but not limited to, any of the following:

    • Active peptic ulcer disease
    • Inflammatory bowel disease (e.g., ulcerative colitis or Crohn disease)
  • No history of bowel obstruction (excluding postoperative (i.e. within 4 weeks post surgery)) during the whole prior history of the patient, or other GI condition with increased risk of perforation such as clear infiltration into the rectosigmoid, colon or small bowel.
  • No clinically significant GI abnormalities that may affect absorption of investigational product including, but not limited to, any of the following:

    • Malabsorption syndrome
    • Major resection of stomach or small bowel
  • No hemoptysis in excess of 2.5 mL (one-half teaspoon) within 8 weeks prior to first dose of study drug
  • No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • No trauma within the past 28 days
  • No prior non-healing wounds, fracture, or ulcer

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No ongoing toxicity from prior anticancer therapy > grade 1 and/or that is progressing in severity, except for alopecia and ≤ grade 2 peripheral neuropathy
  • No cardiac angioplasty or stenting within the past 6 months
  • No coronary artery bypass graft surgery within the past 6 months
  • At least 14 days since prior radiotherapy, surgery, or tumor embolization , chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy (28 days for drugs with a longer half-life)
  • At least 14 days since prior (28 days for drugs with a longer half-life) and no concurrent prohibited medications
  • At least 28 days since prior major surgery (procedures such as catheter placement and diagnostic endoscopic procedures are not considered to be major)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01402271

Contacts
Contact: Ellen Peeters ellen.peeters@eortc.be

Locations
Belgium
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet Recruiting
Brussels, Belgium
Principal Investigator: Joseph Kerger         
U.Z. Gasthuisberg Recruiting
Leuven, Belgium
Principal Investigator: Ignace Vergote, MD, PhD         
C.H.U. Sart-Tilman Recruiting
Liege, Belgium
Principal Investigator: Frederic Kridelka         
Centre Hospitalier Regional De La Citadelle Recruiting
Liege, Belgium
Principal Investigator: Chantal Leroy         
ZNA Jan Palfijn Recruiting
Merksem, Belgium
Principal Investigator: Aldrik Nielander         
Netherlands
Radboud University Medical Center Nijmegen Recruiting
Nijmegen, Netherlands
Principal Investigator: Nelleke Ottevanger         
Erasmus MC Recruiting
Rotterdam, Netherlands
Contact: Ingrid Boere, MD,PhD         
Principal Investigator: Ingrid Boere, MD, PhD         
Spain
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) Recruiting
Badalona, Spain
Principal Investigator: Margarita Romeo         
Hospital Clínico Universitario San Carlos Recruiting
Madrid, Spain
Contact: Antonio Casado, MD, PhD         
Principal Investigator: Antonio Casado, MD, PhD         
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
Study Chair: Ignace B. Vergote, MD, PhD University Hospital, Gasthuisberg
Principal Investigator: Ingrid Boere, MD, PhD Erasmus MC
Principal Investigator: Antonio Casado, MD, PhD Hospital Clínico Universitario San Carlos
  More Information

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT01402271     History of Changes
Other Study ID Numbers: EORTC-55092
EU-21119
2010-024077-39 ( EudraCT Number )
Study First Received: July 23, 2011
Last Updated: October 11, 2016

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
recurrent ovarian epithelial cancer
recurrent fallopian tube cancer
recurrent primary peritoneal cavity cancer

Additional relevant MeSH terms:
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Abdominal Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Fallopian Tube Diseases
Adnexal Diseases
Genital Diseases, Female
Carboplatin
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on March 22, 2017